B-K9 produces mouse IgG1 immunoglobulins directed against a 110 kD protein known as human CD106. It reacts with approximately 15% of peripheral lymphocytes and between 30-90% activated HUVEC
Antigen distribution: CD106 antigen binds the integrins a4b1 (CD49d/CD29, VLA-4) and a4b7 [4]. VLA-4 is the dominant ligand in cells expressing both integrins. Endothelial CD106 contributes to the extravasation of lymphocytes, monocytes, basophils and eosinophils (but not neutrophils) from blood vessels, especially at sites of inflammation. The VLA-4 interaction can mediate both the initial tethering and rolling of lymphocytes on endothelium as well as their subsequent arrest and firm adhesion [5]. CD106 expression on non-vascular tissues is thought to play a role in the interaction of hematopoietic progenitors with bone marrow stromal cells, B cell binding to follicular dendritic cells, co-stimulation of T cells and embryonic development [1,2,3]. Cellular Expression: VCAM-1. Vascular endothelium, dendritic cells, macrophages